Latest Breaking News On - சிகிச்சை வடிவங்கள் - Page 1 : comparemela.com
Alkermes Presented New Data Analysis on Healthcare Resource Use Among Veterans With Alcohol Dependence
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Alkermes Presented New Data Analysis on Healthcare Resource Use Among Veterans With Alcohol Dependence
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
estrogen-receptor-negative
HER2-negative
This means that the growth of the cancer isn’t driven by the hormones estrogen or progesterone, or by the HER2 protein. So, triple-negative breast cancer doesn’t respond to hormonal therapy medicines or medicines that target HER2 protein receptors. About 15% of breast cancers are triple-negative.
Triple-negative breast cancers tend to be:
considered more aggressive than hormone-receptor-positive or HER2-positive breast cancer, mainly because there are few targeted therapy medicines that treat triple-negative breast cancer; studies suggest that triple-negative breast cancer is more likely to spread beyond the breast and more likely to come back after treatment (recur) than other types of breast cancer
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy .
Helsinn Healthcare S.A.February 18, 2021 GMT
Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safety
Lugano, Switzerland, February 18, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to note two recent journal publications on the use of mechlorethamine gel 0.016% as a topical treatment of early stage mycosis fungoides-type cutaneous T-cell lymphoma (“MF-CTCL”).
Mechlorethamine gel 0.016%, also known as chlormethine gel, is approved for use in multiple countries including the US and EU and is marketed under the trade names VALCHLOR® and LEDAGA®. The authorized use for each country varies based on the design of the registrational trial and the individual hea
Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safety
Helsinn announces publication of latest mechlorethamine gel
research, highlighting its efficacy and safety
Lugano, Switzerland, February 18, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to note two recent journal publications on the use of mechlorethamine gel 0.016% as a topical treatment of early stage mycosis fungoides-type cutaneous T-cell lymphoma (“MF-CTCL”).
Mechlorethamine gel 0.016%, also known as chlormethine gel, is approved for use in multiple countries including the US and EU and is marketed under the trade names VALCHLOR
® and LEDAGA
vimarsana © 2020. All Rights Reserved.